SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase II trial is studying how well SB939 works in treating patients with
recurrent or metastatic prostate cancer.